Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - April 2013

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Insulin degludec (Tresiba®) has been rejected for use in the treatment of diabetes mellitus in adults. The manufacturer failed to make a sufficiently robust economic case.

Insulin glargine (Lantus®) has been accepted for restricted use in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. The restriction recommends use in patients with Type 1 diabetes when efforts to achieve better glycaemic control result in unacceptable levels of nocturnal hypoglycaemia or to aid carer administration. In patients with Type 2 diabetes use is recommended for patients who experience recurrent episodes of hypoglycaemia or require assistance with their insulin injections.

Timothy grass pollen allergen (GRAZAX®) has been rejected for use as a disease-modifying treatment of grass pollen induced rhinitis and conjunctivitis in adults and children. The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - April 2013' on Email Share 'SMC Update - April 2013' on Delicious Share 'SMC Update - April 2013' on Digg Share 'SMC Update - April 2013' on Facebook Share 'SMC Update - April 2013' on Google+ Share 'SMC Update - April 2013' on reddit Share 'SMC Update - April 2013' on StumbleUpon Share 'SMC Update - April 2013' on Twitter

atomic-wealth

No Comments to “SMC Update - April 2013”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer